TOP TEN perturbations for 39648_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39648_at
Selected probe(set): 205160_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39648_at (205160_at) across 6674 perturbations tested by GENEVESTIGATOR:
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-2.9395752Number of Samples:3 / 3
| Experimental | echinomycin study 1 |
| Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
| Control | deferoxamine study 5 |
| Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)
Relative Expression (log2-ratio):2.7763176Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (subconfluent) |
| Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert. |
bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)
Relative Expression (log2-ratio):2.5199747Number of Samples:3 / 3
| Experimental | bronchial epithelial cell differentiation study 1 (day28) |
| Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour. | |
| Control | bronchial epithelial cell differentiation study 1 (confluent) |
| Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert. |
Hep-G2 / HepaRG
Relative Expression (log2-ratio):-2.4073162Number of Samples:9 / 12
| Experimental | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: | |
| Control | HepaRG |
| Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary)
Relative Expression (log2-ratio):-2.300211Number of Samples:2 / 2
| Experimental | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary) |
| Primary tumor tissue samples obtained from the breast of patients with intraductal papillary adenocarcinoma with invasion. |
DMN study 1 (24h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):-2.2008905Number of Samples:3 / 7
| Experimental | DMN study 1 (24h) |
| HepG2 cells exposed to 2mM dimethyl nitrosamine (DMN) in DMSO solvent for 24 hours. ATC code:--- | |
| Control | vehicle (DMSO) treated HepG2 cell sample |
| HepG2 cells exposed to DMSO solvent for 24 hours. |
expO breast cancer study 1 (medullary carcinoma, NOS; primary) / expO breast cancer study 1 (intraductal carcinoma; in situ)
Relative Expression (log2-ratio):-2.1461802Number of Samples:2 / 3
| Experimental | expO breast cancer study 1 (medullary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with medullary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (intraductal carcinoma; in situ) |
| Tumor tissue samples obtained from the breast of patients with intraductal carcinoma. |
ulcerative colitis study 17 (5-ASA / AZA) / ulcerative colitis study 17 (5-ASA)
Relative Expression (log2-ratio):-2.1259775Number of Samples:2 / 2
| Experimental | ulcerative colitis study 17 (5-ASA / AZA) |
| Mucosa tissue from sigmoid colon derived from patients with ulcerative colitis treated with mesalazine (5-ASA) in combination with azathioprine (AZA). Biopsies were collected from non-inflamed tissue and histological examination showed no cellular infiltration or tissue damage. Ulcerative colitis (UC) was diagnosed based on endoscopic, histological and radiological criteria and based on a permanent, colon exclusive, inflammation state. All patients showed mild to active disease state (colitis activity index from 2 to 7) and received no antibiotic therapy at least in the last 6 months before investigation. All patients investigated are UC discordant twins. | |
| Control | ulcerative colitis study 17 (5-ASA) |
| Mucosa tissue from sigmoid colon derived from patients with ulcerative colitis treated with mesalazine (5-ASA). Biopsies were collected from non-inflamed tissue and histological examination showed no cellular infiltration or tissue damage. Ulcerative colitis (UC) was diagnosed based on endoscopic, histological and radiological criteria and based on a permanent, colon exclusive, inflammation state. All patients showed mild to active disease state (colitis activity index from 2 to 7) and received no antibiotic therapy at least in the last 6 months before investigation. All patients investigated are UC discordant twins. |
expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary) / expO breast cancer study 1 (inflammatory carcinoma; primary)
Relative Expression (log2-ratio):2.0815287Number of Samples:2 / 2
| Experimental | expO breast cancer study 1 (intraductal papillary adenocarcinoma with invasion; primary) |
| Primary tumor tissue samples obtained from the breast of patients with intraductal papillary adenocarcinoma with invasion. | |
| Control | expO breast cancer study 1 (inflammatory carcinoma; primary) |
| Primary tumor tissue samples obtained from the breast of patients with inflammatory carcinoma. |
expO breast cancer study 1 (metaplastic carcinoma, NOS; primary) / expO breast cancer study 1 (intraductal carcinoma; in situ)
Relative Expression (log2-ratio):-2.0292702Number of Samples:3 / 3
| Experimental | expO breast cancer study 1 (metaplastic carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with metaplastic carcinoma (NOS). | |
| Control | expO breast cancer study 1 (intraductal carcinoma; in situ) |
| Tumor tissue samples obtained from the breast of patients with intraductal carcinoma. |